Adiponectin: a link between obesity and cancer
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Adiponectin, an insulin-sensitising hormone produced by adipocytes, has direct antidiabetic, antiatherogenic, anti-inflammatory and antiangiogenic properties. Circulating adiponectin levels are lower in obesity, a disease state that is associated with certain malignancies. Recently, accumulating evidence suggests that adiponectin may have an important protective role in carcinogenesis. There is also evidence that at least some, if not most, cancer cell types express adiponectin receptors; thus adiponectin may act on tumour cells directly by binding and activating adiponectin receptors and downstream signalling pathways. Through its antiangiogenic properties, and also possibly through other mechanisms regulating cell proliferation discussed in this review, adiponectin may prove to be an effective novel anticancer agent. Large association and prospective studies to assess adiponectin levels in relation to risk from cancer, as well as mechanistic studies to prove adiponectin's role in the development of malignancies, and interventional trials to address potential roles of adiponectin in cancer pathogenesis and therapeutics are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Adipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915 · cited 1×
“Several signalling molecules besides AMPK, such as PPAR-α, p38 MAPK [129] and, recently, c-Jun N-terminal kinase (JNK) and signal transducer and activator of transcription 3 (STAT3) [65], are also known to mediate adiponectin effects.”
BackgroundParadoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795 · cited 1×
“The number of obese individuals is expected to continue to rise such that by the year 2030 it is anticipated that close to 50% of the US or close to 30% of the European population will be obese [2].”
BackgroundYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238 · cited 2×
“, AMPK activation by adiponectin leads to increase fatty-acid oxidation, glucose uptake and lactate production in muscle, and reduction of molecules involved in gluconeogenesis in the liver, and thus reduction of glucose levels in vivo) [58,60].”
BackgroundSignal transduction by the JNK group of MAP kinases
Davis, R. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00116-1 · Cited by 4,237 · cited 2×
“It is also a crucial mediator of obesity and insulin resistance [138,139].”
BackgroundTSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., & Tataranni, P. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7463 · Cited by 3,541
A central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359 · cited 1×
“It is also a crucial mediator of obesity and insulin resistance [138,139].”
Background
Cited by
Manna, P., & Jain, S. K. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.0095 · Cited by 1,145
Boutari, C., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155217 · Cited by 1,068
“Epidemiologic studies have revealed an association between high body mass index (BMI) and an extensive range of chronic diseases such as Non Alcoholic Fatty Liver (NAFL), cardiovascular disease [1,2], diabetes mellitus [1], several malignancies [3,4], musculoskeletal diseases [5,6], chronic kidney disease [1], and men…”
Self-citationAdipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression
Vona-Davis, L., & Rose, D. P. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-06-0068 · Cited by 496
“Mantzoros and colleagues (Barb et al. 2006, Kelesidis et al. 2006) showed that adiponectin can act on T47D breast cancer cells directly and alter downstream signaling pathways. The effects of adiponectin on growth were mediated by the activation of ERK1/2 and not by adenosine monophosphate-activated protein kinase (AM…”
BackgroundBlüher, M., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.016 · Cited by 399
Self-citationAdiponectin in relation to malignancies: a review of existing basic research and clinical evidence
Barb, D., Williams, C. J., Neuwirth, A. K., & Mantzoros, C. S. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.858s · Cited by 338
Self-citationAdiponectin action from head to toe
Brochu-Gaudreau, K., Rehfeldt, C., Blouin, R., Bordignon, V., Murphy, B. D., & Palin, M.-F. (2010) · Endocrine · doi:10.1007/s12020-009-9278-8 · Cited by 322
Plasma Adiponectin Concentrations and Risk of Incident Breast Cancer
Tworoger, S. S., Eliassen, A. H., Kelesidis, T., Colditz, G. A., Willett, W. C., Mantzoros, C. S., & Hankinson, S. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1975 · Cited by 284
Self-citationObesity, DNA Damage, and Development of Obesity-Related Diseases
Włodarczyk, M., & Nowicka, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051146 · Cited by 242
“Some tumor cells express adiponectin receptors, thus adiponectin by binding and activating these receptors can downstream signaling pathways in cancer cells and adiponectin deficiency excludes such action [139,140].”
BackgroundObesity-associated Breast Cancer: Analysis of risk factors
Engin, A. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-48382-5_25 · Cited by 178
Taliaferro-Smith, L., Nagalingam, A., Zhong, D., Zhou, W., Saxena, N. K., & Sharma, D. (2009) · Oncogene · doi:10.1038/onc.2009.129 · Cited by 172
“Adiponectin treatment decreases adhesion as well as invasion and migration of breast cancer cells Epidemiological studies have shown that low adiponectin levels are significantly associated with an increased breast tumor growth and metastasis (Miyoshi et al., 2003; Mantzoros et al., 2004; Barb et al., 2006; Chen et al…”
Larsson, S. C., Spyrou, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155326 · Cited by 89
Self-citationNoormohammadi, M., Ghorbani, Z., Löber, U., Mahdavi-Roshan, M., Bartolomaeus, T. U. P., Kazemi, A., Shoaibinobarian, N., & Forslund, S. K. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106614 · Cited by 40
Metadata
- Authors
- Barb, D., Pazaitou-Panayiotou, K., & Mantzoros, C. S.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2006-07-21
- Volume
- 15
- Issue
- 8
- Pages
- 917-931
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2011382710
- Cited by
- 121
- References
- 30
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.